The US Food and Drug Administration (FDA) has approved the targeted interleukin (IL)-13 inhibitor lebrikizumab (Ebglyss) for the treatment of adults and children age 12 years and older who have ...

Atopic dermatitis (AD) monotherapy with the lebrikizumab, an interleukin-13 inhibitor, was shown to be both effective and safe in the induction periods of the phase 3 ADvocate1 and ADvocate2 trials, ...

ADorable-1 randomized 367 pediatric patients after a 2-week topical corticosteroid run-in to weight-based subcutaneous lebrikizumab versus placebo, with week-16 coprimary end points IGA 0/1 and ...

In the ADlong Phase 3b study, nearly all EBGLYSS-treated patients achieved meaningful skin improvement (EASI-75) for up to four years 75% of patients achieved a high bar of near-complete skin ...

Patients could soon have access to a new injectable drug to treat atopic dermatitis, the most common form of eczema. The drug, lebrikizumab, proved effective in teenagers and adults in two clinical ...

The FDA has approved lebrikizumab (Ebglyss; Eli Lilly) as a new first-line biologic treatment for patients aged 12 and older with moderate to severe atopic dermatitis (AD). The FDA approved ...

EBGLYSS provides a new first-line biologic treatment for moderate-to-severe atopic dermatitis that is not well controlled with topicals Patients treated with EBGLYSS experienced significant skin ...

Lebrikizumab, a high-affinity IgG4 monoclonal antibody targeting interleukin-13, prevents the formation of the interleukin-4Rα–interleukin-13Rα1 heterodimer receptor signaling complex. We conducted ...

Monthly EGBLYSS maintenance dosing sustained clear or almost-clear skin for up to three years in the vast majority of ADvocate 1 and 2 responders Nearly 87 percent of patients taking EBGLYSS did not ...

Please provide your email address to receive an email when new articles are posted on . Both 2-week and monthly dosing of lebrikizumab maintained skin clearance and reduced itch among patients with ...

Monthly lebrikizumab maintenance dosing sustained clear or almost-clear skin for up to three years in the vast majority (more than 80%) of ADvocate 1 and 2 responders Nearly 87 percent of patients ...